Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $17.1667.

KPTI has been the subject of several recent analyst reports. Piper Sandler reiterated an “overweight” rating and set a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. Robert W. Baird dropped their price objective on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a research note on Wednesday, March 25th. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Finally, HC Wainwright increased their target price on Karyopharm Therapeutics from $8.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th.

Karyopharm Therapeutics Trading Down 5.6%

Shares of NASDAQ KPTI opened at $9.10 on Wednesday. The business has a fifty day simple moving average of $8.61 and a 200 day simple moving average of $7.74. The firm has a market capitalization of $206.23 million, a price-to-earnings ratio of -0.60 and a beta of 0.83. Karyopharm Therapeutics has a one year low of $3.65 and a one year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.21. The company had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million. On average, research analysts anticipate that Karyopharm Therapeutics will post -3.24 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Several large investors have recently made changes to their positions in the business. Royal Bank of Canada grew its holdings in shares of Karyopharm Therapeutics by 4.1% during the first quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock worth $336,000 after purchasing an additional 2,399 shares during the last quarter. Corient Private Wealth LLC bought a new position in Karyopharm Therapeutics in the fourth quarter valued at about $74,000. Baird Financial Group Inc. bought a new position in Karyopharm Therapeutics in the second quarter valued at about $45,000. Hsbc Holdings PLC bought a new position in Karyopharm Therapeutics in the first quarter valued at about $66,000. Finally, State Street Corp boosted its holdings in Karyopharm Therapeutics by 27.2% in the fourth quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after acquiring an additional 12,600 shares during the last quarter. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.